Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)

Código QR

Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)

Nicholas Giustini, Lyudmila Bazhenova UCSD Moores Cancer Center, Department of Hematology and Oncology, 3855 Health Sciences Drive MC #0987, La Jolla, CA, 92093-0829, USACorrespondence: Nicholas Giustini 3855 Health Sciences Drive #0829, La Jolla, CA, 92093-0829 Email ngiustini@health.ucsd.eduAbstra...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Giustini N, Bazhenova L
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	nsclc immunotherapy biomarkers Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/d1a3a4b3ebf44cf6bfd02cde9b7868d4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Severe hyponatremia due to paraneoplastic syndrome of inappropriate antidiuretic hormone secretion in non-small cell lung carcinoma transforming to small cell lung carcinoma during treatment with immune checkpoint inhibitor
por: Vicky Mai, et al.
Publicado: (2021)

Prognostic value of microRNA-4521 in non-small cell lung cancer and its regulatory effect on tumor progression
por: Sun Butong, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors With or Without Bone-Targeted Therapy in NSCLC Patients With Bone Metastases and Prognostic Significance of Neutrophil-to-Lymphocyte Ratio
por: Alberto Bongiovanni, et al.
Publicado: (2021)

Clinical Trial Progress and Application of Immune Checkpoint Inhibitors  in the Treatment of Small Cell Lung Cancer
por: Huiqiu ZHANG, et al.
Publicado: (2021)

Identification of circRNA_001846 as putative non–small cell lung cancer biomarker
por: Fan Yang, et al.
Publicado: (2021)

Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management
por: Maja Šutić, et al.
Publicado: (2021)

Overweight as a Favorable Clinical Biomarker for Checkpoint Inhibitor Therapy Response in Recurrent Gynecologic Cancer Patients
por: Thomas Bartl, et al.
Publicado: (2021)

Clinical Management and Outcome of Grade III Pneumonitis after Chemoradioimmunotherapy for Inoperable Stage III Non-Small Cell Lung Cancer—A Prospective Longitudinal Assessment
por: Diego Kauffmann-Guerrero, et al.
Publicado: (2021)

Identification and Validation of an Immune and Ferroptosis-Combined Index for Non–Small Cell Lung Cancer
por: Yang Teng, et al.
Publicado: (2021)

Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current Evidence
por: Sara Elena Rebuzzi, et al.
Publicado: (2021)

Advances in Biomarkers for Immunotherapy of Non-small Cell Lung Cancer
por: Chuan HUANG, et al.
Publicado: (2021)

Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival
por: Fiamma Berner, et al.
Publicado: (2021)

Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer
por: Weinberg F, et al.
Publicado: (2019)

A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer
por: Alessio Bruni, et al.
Publicado: (2021)

Corrigendum: A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer
por: Alessio Bruni, et al.
Publicado: (2021)

A Pilot Study to Evaluate Early Predictive Value of Thorax Perfusion-CT in Advanced NSCLC
por: Francisco Aya, et al.
Publicado: (2021)

Integrated Bioinformatics Analysis Identifies Heat Shock Factor 2 as a Prognostic Biomarker Associated With Immune Cell Infiltration in Hepatocellular Carcinoma
por: Yumei Fan, et al.
Publicado: (2021)

Immunotherapy in the First-Line Treatment of NSCLC: Current Status and Future Directions in China
por: Anwen Xiong, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers
por: Brian W. Labadie, et al.
Publicado: (2021)

Small cell lung cancer transformation during antitumor therapies: A systematic review
por: Chai Xing, et al.
Publicado: (2021)

New targeted treatments for non-small-cell lung cancer – role of nivolumab
por: Zago G, et al.
Publicado: (2016)

Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status
por: Kyoichi Kaira, et al.
Publicado: (2021)

Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling
por: Joseph D Butner, et al.
Publicado: (2021)

Correlation of serum electrolytes with serial miRNA in advanced stage non-small cell lung cancer (NSCLC) in Indonesia
por: Arif Riswahyudi Hanafi, et al.
Publicado: (2021)

circ_0005962 functions as an oncogene to aggravate NSCLC progression
por: Zhang Zhihong, et al.
Publicado: (2021)

Neoadjuvant immunotherapy combined with chemotherapy for locally advanced squamous cell lung carcinoma: A case report and literature review
por: Zheng Yuan, et al.
Publicado: (2021)

Age-Based Disparities in Metastatic Melanoma Patients Treated in the Immune Checkpoint Inhibitors (ICI) Versus Non-ICI Era: A Population-Based Study
por: Mohammed Safi, et al.
Publicado: (2021)

Potential utility of longitudinal somatic mutation and methylation profiling for predicting molecular residual disease in postoperative non‐small cell lung cancer patients
por: Hang Li, et al.
Publicado: (2021)

Clinical Research Progress of Radiotherapy Combined with Immune Checkpoint Inhibitors on NSCLC
por: ZHU Kuikui, et al.
Publicado: (2021)

Radiation pneumonitis in patients with non-small-cell lung cancer receiving chemoradiotherapy and an immune checkpoint inhibitor: a retrospective study
por: Jeong Yun Jang, et al.
Publicado: (2021)

miRNA as a Modulator of Immunotherapy and Immune Response in Melanoma
por: Mai-Huong Thi Nguyen, et al.
Publicado: (2021)

Identification of lncRNA–miRNA–mRNA Networks Linked to Non-small Lung Cancer Resistance to Inhibitors of Epidermal Growth Factor Receptor
por: Ting Wang, et al.
Publicado: (2021)

Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Xiuqiong Chen, et al.
Publicado: (2021)

Prognostic characterization of immune molecular subtypes in non-small cell lung cancer to immunotherapy
por: Chenlu Li, et al.
Publicado: (2021)

Bevacizumab in the treatment of NSCLC: patient selection and perspectives
por: Russo AE, et al.
Publicado: (2017)

Evaluation of Predictive Values of Naples Prognostic Score in Patients with Unresectable Stage III Non-Small Cell Lung Cancer
por: Guo D, et al.
Publicado: (2021)

Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib
por: Mengqiu Tang, et al.
Publicado: (2021)

Comprehensive Analysis of Inhibitor of Apoptosis Protein Expression and Prognostic Significance in Non–Small Cell Lung Cancer
por: Jun Liu, et al.
Publicado: (2021)

Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [<sup>18</sup>F]FDG PET/CT in Metastatic Melanomas and Lung Cancer
por: Egesta Lopci
Publicado: (2021)

Combination Cancer Immunotherapy of Nanoparticle-Based Immunogenic Cell Death Inducers and Immune Checkpoint Inhibitors
por: Qi J, et al.
Publicado: (2021)